Segment Information and Concentration of Business Risk (Tables)

12 Months Ended

Dec. 31, 2015

Segment Information and Concentration of Business Risk [Abstract]

Segment Information

The following is our segment information for 2015 (in thousands):

2015	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
Research and development	$	285,608		$	—		$	(4,248	)	$	281,360
Licensing and royalty		2,343			—			—			2,343
Total segment revenue	$	287,951		$	—		$	(4,248	)	$	283,703
Loss from operations	$	(21,378	)	$	(54,384	)	$	—		$	(75,762	)
Total assets	$	1,004,150		$	55,354		$	(103,399	)	$	956,105

The following is our segment information for 2014 and 2013 (in thousands) revised for comparative purposes to show operating expense for Akcea-related projects in 2014 and 2013:

2014	Ionis Core			Akcea Therapeutics			Total
Revenue:
Research and development	$	202,514		$	—		$	202,514
Licensing and royalty		11,647			—			11,647
Total segment revenue	$	214,161		$	—		$	214,161
Loss from operations	$	(26,033	)	$	(21,697	)	$	(47,730	)

2013	Ionis Core			Akcea Therapeutics			Total
Revenue:
Research and development	$	147,380		$	—		$	144,194
Licensing and royalty		3,091			—			3,091
Total segment revenue	$	150,471		$	—		$	147,285
Loss from operations	$	(38,764	)	$	(12,902	)	$	(51,666	)

Revenue from Significant Partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:

	2015		2014		2013
Partner A		37 %		58 %		25 %
Partner B		33 %		0 %		0 %
Partner C		12 %		17 %		24 %
Partner D		11 %		4 %		3 %
Partner E		2 %		13 %		20 %
Partner F		0 %		0 %		22 %